Nagesh Mahanthappa

Nagesh is an advisor to biotechnology companies with a particular interest in start-up and early-stage ventures focused on the discovery and development of novel therapeutics. He was mostly recently the founding CEO of Scholar Rock, Inc.; during his eight-year tenure, Nagesh took the biotech company public and lead two distinct drug candidates into clinical testing. Previous experiences include being the founding employee and VP of Corporate Development at Avila Therapeutics, Inc. (acquired by Celgene in 2012), and founding employee of Alnylam Pharmaceuticals where he rose to VP, Scientific & Strategic Development. Prior roles include positions at Vertex Pharmaceuticals, and Ontogeny (now Curis, Inc.). Nagesh started in biotech as a scientist at Cambridge NeuroScience, and was a founder of TwistDx, a molecular diagnostics company (now a part of Abbott).

Nagesh completed post-doctoral training at E.K. Shriver Center for Mental Retardation (an affiliate of Massachusetts General Hospital) and Harvard Medical School after receiving his Ph.D. in Neurobiology from the California Institute of Technology. Nagesh received his B.A. in Biology and Chemistry from the University of Colorado, and his M.B.A. from the F.W. Olin Graduate School of Management at Babson College.